96
Views
22
CrossRef citations to date
0
Altmetric
Review

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis

&
Pages 469-479 | Published online: 12 May 2014

Figures & data

Table 1 Study characteristics of included trials that provide data on the total number of exacerbations and/or the mean annual rate of exacerbations

Figure 1 Flow of study selection.

Figure 1 Flow of study selection.

Figure 2 Diagram displaying the network of eight arms involved in the Bayesian analyses.

Notes: The links between nodes are used to indicate a direct comparison between pairs of treatments. The numbers shown along the link lines indicate the number of trials comparing pairs of treatments head-to-head.
Abbreviations: BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; ICS, inhaled corticosteroids; LABA, long-acting beta agonists; MF, mometasone furoate; PLB, placebo; SAL, salmeterol; VI, vilanterol.
Figure 2 Diagram displaying the network of eight arms involved in the Bayesian analyses.

Figure 3 Pooled effect estimate on moderate-to-severe exacerbations for all combined inhalers versus placebo.

Abbreviations: BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; MF, mometasone furoate; SAL, salmeterol; VI, vilanterol.

Figure 3 Pooled effect estimate on moderate-to-severe exacerbations for all combined inhalers versus placebo.Abbreviations: BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; MF, mometasone furoate; SAL, salmeterol; VI, vilanterol.

Figure 4 Pooled effect estimate on moderate-to-severe exacerbations for all combined inhalers versus long acting beta-agonist.

Abbreviations: BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; MF, mometasone furoate; SAL, salmeterol; VI, vilanterol.
Figure 4 Pooled effect estimate on moderate-to-severe exacerbations for all combined inhalers versus long acting beta-agonist.

Figure 5 Pooled effect estimate on severe exacerbations for all combined inhalers versus placebo.

Abbreviations: BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; MF, mometasone furoate; SAL, salmeterol; VI, vilanterol.

Figure 5 Pooled effect estimate on severe exacerbations for all combined inhalers versus placebo.Abbreviations: BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; MF, mometasone furoate; SAL, salmeterol; VI, vilanterol.

Figure 6 Pooled effect estimate on severe exacerbations for all combined inhalers versus long acting beta-agonist.

Abbreviations: BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; MF, mometasone furoate; SAL, salmeterol; VI, vilanterol.
Figure 6 Pooled effect estimate on severe exacerbations for all combined inhalers versus long acting beta-agonist.

Table S1 Definitions of COPD exacerbations in the included trials